Biotechnology - Asia-Pacific, Oncology

Filter

Current filters:

Asia-PacificOncology

Popular Filters

1 to 25 of 27 results

Seattle Genetics earns $6 million milestone under Adcetris accord with Takeda

Seattle Genetics earns $6 million milestone under Adcetris accord with Takeda

08-04-2014

US biotech firm Seattle Genetics says it will receive milestone payments from Japan’s Takeda Pharmaceutical…

AdcetrisAsia-PacificBiotechnologyFinancialMarkets & MarketingOncologySeattle GeneticsSouth AmericaTakeda Pharmaceuticals

Walvax Biotech to take 64% stake in Genor BioPharma for around $49 million

Walvax Biotech to take 64% stake in Genor BioPharma for around $49 million

31-12-2013

China’s Walvax Biotech has revealed it plans to acquire a controlling 64% equity stake in Shanghai’s…

Asia-PacificBiosimilarsBiotechnologyChinaMergers & AcquisitionsOncology

Drug approvals for Bayer in USA and Japan

Drug approvals for Bayer in USA and Japan

23-11-2013

There were two pieces of good news for German Pharma and chemicals major Bayer on Friday (November 22),…

AmgenAsia-PacificBayerBiotechnologyEyleaNexavarNorth AmericaOncologyOnyx PharmaceuticalsOphthalmicsPharmaceuticalRegeneronRegulation

Merck Serono signs $232 million deal with Chinese company for BeiGene-290

Merck Serono signs $232 million deal with Chinese company for BeiGene-290

13-11-2013

Merck Serono has signed a global licensing, co-development and commercialization agreement for BeiGene-290…

Asia-PacificBeiGeneBiotechnologyChinaLicensingMerck SeronoOncology

Immutep and Eddingpharm sign accord for ImmuFact IMP321 in China

07-10-2013

French biopharma Immutep and Chinese drugmaker Eddingpharm have entered into an agreement for the development,…

Asia-PacificBiotechnologyLicensingMarkets & MarketingOncologyResearch

Bayer gets Japanese OK for GI stromal tumors drug

20-08-2013

German drug major Bayer (BAYN: DE) has received approval from the Ministry of Health, Labor and Welfare…

Asia-PacificBayerBiotechnologyOncologyPharmaceuticalRegulationStivarga

Bristol-Myers partners with South Korean firm on biopharma production

29-07-2013

US pharma major Bristol-Myers Squibb (NYSE: BMY) has entered into a 10-year agreement under which Samsung…

Asia-PacificBiotechnologyBristol-Myers SquibbOncologyPharmaceuticalProductionSamsung BioLogics

Soligenix collaborates with SciClone in China for SGX942 as oral mucositis therapy

09-07-2013

US clinical-stage biopharma firm Soligenix (OTCQB: SNGX) has entered into a personalized medicine collaboration…

Asia-PacificBiotechnologyLicensingOncologyResearchSciClone PharmaSGX942Soligenix

Additional indications in Japan for Roche's Avastin and Astellas' Prograf

17-06-2013

Swiss drug major Roche (ROG: SIX) says that the Japanese Ministry of Health, Labor and Welfare (MHLW)…

Asia-PacificAstellas PharmaAvastinBiotechnologyImmunologicalsOncologyPharmaceuticalPrografRegulationRoche

Amgen and Astellas link up on drugs for unmet medical needs in Japan

29-05-2013

World leading independent biotech firm Amgen (Nasdaq: AMGN) has joined forces with Japanese drug major…

AmgenAnti-Arthritics/RheumaticsAsia-PacificAstellas PharmaBiotechnologyCardio-vascularOncologyPharmaceuticalResearch

CMC Biologics and RuiYi link on MAb; Deal for Cynviloq rights in EU

14-05-2013

Denmark and USA-based contract manufacturers CMC Biologics has entered into an agreement with China's…

Asia-PacificBiotechnologyCMC BiologicsCynviloqEuropeIGDRASOLLicensingOncologyPharmaceuticalResearchRuiYiSamyang BiopharmaceuticalsSorrento Therapeutics

New Zealand considers listing of Neulastim and Actemra

12-04-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list pegfilgrastim…

ActemraAnti-Arthritics/RheumaticsAsia-PacificBiotechnologyNeulastimOncologyPharmaceuticalPricingRegulationRoche

Celgene's Revlimid approved in China for MM; gets PDUFA date in USA for mantle cell lymphoma

12-02-2013

Celgene Corp's (Nasdaq: CELG) European subsidiary revealed that Revlimid (lenalidomide) has been granted…

Asia-PacificBiotechnologyCelgeneNorth AmericaOncologyRegulationRevlimid

Kyowa Hakko set to file for pegfilgrastim approval in Japan following strong Ph III data

28-01-2013

Mid-size Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) on Friday released positive top-line results…

Asia-PacificBiotechnologyKyowa Hakko KirinOncologypegfilgrastimPharmaceuticalRegulationResearch

Nexavar use in Chinese patients nearly doubled in 2012

19-12-2012

Use of Nexavar (sorafenib, from Bayer [BAYN: DE] and Onyx Pharmaceuticals) has nearly doubled in first-line…

AlimtaAsia-PacificBayerBiotechnologyEli LillyMarkets & MarketingNexavarOncologyPharmaceutical

News briefs on Ipsen/Galderma and YM BioSciences nimotuzumab assets

04-12-2012

French drugmaker Ipsen (Euronext: IPN) and Switzerland-headquartered Galderma have expanded their collaboration…

Asia-PacificBiotechnologyCIMABDysportGaldermaInnoKeys PTEIpsenLicensingnimotuzumabOncologyPharmaceuticalSouth AmericaYM Biosciences

Regulatory briefs: Celgene's pomalidomide; Lundbeck's vortioxetine

21-09-2012

US biotech firm Celgene (Nasdaq: CELG) says that the US Food and Drug Administration's Oncologic Drugs…

Asia-PacificBiotechnologyCelgeneLundbeckNeurologicalNorth AmericaOncologyPharmaceuticalpomalidomideRegulationvortioxetine

PharmaEngine and Nanobiotix sign Asia-Pacific deal for NBTXR3

08-08-2012

French nano-medicines group Nanobiotix has entered into a strategic partnership with PharmaEngine (TWO:…

Asia-PacificBiotechnologyLicensingNanobiotixNBTXR3OncologyPharmaceuticalPharmaEngine

Alnylam and Ascletis collaborate to develop ALN-VSP for liver cancers in China

15-07-2012

US RNAi therapeutics specialties Alnylam Pharmaceuticals (Nasdaq: ALNY) and Ascletis Pharmaceuticals,…

ALN-VSPAlnylam PharmaceuticalsAscletis PharmaceuticalsAsia-PacificBiotechnologyLicensingOncology

China's Hisun gains access to Enzon technology

17-05-2012

US biotech firm Enzon Pharmaceuticals (Nasdaq: ENZN) and Chinese drugmaker Zhejiang Hisun Pharmaceuticals…

Asia-PacificBiotechnologyEnzon PharmaceuticalsLicensingOncologyPEG-SN38PharmaceuticalZhejiang Hisun Pharma

Daiichi Sankyo debuts bone cancer drug Ranmark in Japan

17-04-2012

Following National Health Insurance price listing yesterday, Japanese drug major Daiichi Sankyo (TYO:…

AmgenAsia-PacificAstraZenecaBiotechnologyDaiichi SankyodenosumabMarkets & MarketingOncologyPharmaceuticalRanmark

Apexigen licenses MAb to Gansu Duyiwei for China

12-03-2012

Privately-held US biopharma firm Apexigen has entered into a collaboration to grant an exclusive license…

ApexigenAsia-PacificBiotechnologyGansu DuyiweiLicensingOncology

1 to 25 of 27 results

Back to top